Ozempic (semaglutide) became one of the most prescribed medications worldwide in recent years. Millions of people use the weekly injection to manage type 2 diabetes or to lose significant amounts of weight. The drug’s ability to lower blood sugar and suppress appetite has helped many achieve impressive health improvements.
However, as usage exploded, reports of serious complications began to surface. Some patients experienced unexpected and sometimes severe side effects that were not fully anticipated when the medication first launched. These problems led to growing concern among users, doctors, and legal professionals.
By 2026, thousands of lawsuits have been filed against Novo Nordisk, the manufacturer of Ozempic. The claims center on alleged failures to adequately warn about certain risks. The phrase Ozempic lawsuit side effects now appears frequently in news reports, patient forums, and legal advertisements.
How Ozempic Works and Why Side Effects Occur
Ozempic belongs to the class of drugs called GLP-1 receptor agonists. It mimics a natural hormone that regulates blood sugar and digestion. The medication slows gastric emptying, increases insulin release when needed, and reduces appetite signals in the brain.
These powerful actions produce excellent results for diabetes control and weight loss. At the same time, the significant slowdown of stomach emptying and changes in gut motility can create problems for some people. When food stays in the stomach much longer than normal, various complications may develop.
Most common side effects (nausea, vomiting, diarrhea) are well-known and listed on the label. The lawsuits focus on rarer but more serious issues that some patients believe were not properly disclosed.
Gastrointestinal Problems at the Center of Lawsuits
Severe stomach and intestinal issues form the largest group of Ozempic lawsuit side effects claims. Patients report conditions that go far beyond typical nausea or mild discomfort.
Gastroparesis (paralysis or extreme slowing of the stomach) is the most frequently mentioned diagnosis. In this condition, the stomach empties so slowly that food remains for days or even weeks, causing chronic nausea, vomiting, bloating, pain, and malnutrition.
Ileus (complete bowel obstruction without a physical blockage) has also been reported in multiple cases. Patients describe unbearable abdominal pain, inability to pass gas or stool, and repeated emergency room visits.
Many lawsuits allege that these problems persisted long after stopping the medication. Some patients required hospitalization, feeding tubes, or surgery to clear blockages.
Gallbladder-Related Claims
Another major category of Ozempic lawsuit side effects involves the gallbladder. Rapid weight loss from GLP-1 medications increases the risk of gallstones and gallbladder inflammation (cholecystitis).
Plaintiffs claim the company failed to sufficiently warn about the possibility of needing emergency gallbladder removal surgery. Some lawsuits describe cases of acute cholecystitis leading to prolonged hospital stays and ongoing digestive difficulties.
Medical experts note that significant weight loss from any method carries a known risk of gallbladder problems. However, the lawsuits argue that the speed and degree of weight loss with semaglutide make the risk higher than adequately communicated.
Vision Loss and NAION Cases
A separate but growing group of lawsuits focuses on sudden vision loss linked to non-arteritic anterior ischemic optic neuropathy (NAION). This condition, sometimes called an “eye stroke,” occurs when blood flow to the optic nerve is reduced.
Several observational studies published between 2024 and 2025 reported higher rates of NAION among semaglutide users compared to people taking other diabetes or weight-loss drugs. The absolute risk remains very low, but the potential for permanent vision impairment has driven legal action.
Plaintiffs in these cases argue that Novo Nordisk knew or should have known about the possible association earlier and failed to update warnings in a timely manner.
Other Alleged Side Effects Mentioned in Lawsuits
Some filings also mention:
- Severe pancreatitis (inflammation of the pancreas)
- Kidney injury or acute kidney failure
- Deep vein thrombosis or pulmonary embolism
- Severe allergic reactions
- Thyroid tumors (based on animal studies)
These claims are less common than gastrointestinal or vision-related lawsuits. Most of them remain under active investigation and have not yet produced large-scale verdicts or settlements.
Current Status of Ozempic Lawsuits (January 2026)
As of January 2026, most Ozempic-related lawsuits have been consolidated into multidistrict litigation (MDL) in the United States. The MDL includes thousands of individual claims and several class-action attempts.
No major bellwether trials have concluded yet. Early discovery phases focus on internal company documents, clinical trial data, and post-marketing surveillance reports. Many legal experts expect the first significant settlements or trial outcomes sometime in 2026–2027.
Outside the United States, similar claims have been filed in Canada, the United Kingdom, and several European countries, though the scale remains smaller than in the U.S.
Current Product Labeling and Company Response
Novo Nordisk maintains that Ozempic’s benefits outweigh its risks when used as directed. The company has updated the label multiple times since 2023 to include stronger warnings about:
- Gastroparesis and ileus
- Gallbladder disorders
- Possible risk of NAION
- Acute pancreatitis
- Acute kidney injury
The manufacturer also points out that many reported complications occur in patients with pre-existing risk factors. They emphasize that the drug remains an important treatment option for millions of people.
Summary
Ozempic lawsuit side effects primarily involve severe gastrointestinal disorders (especially gastroparesis and ileus), gallbladder problems, and rare cases of sudden vision loss from NAION. Thousands of lawsuits claim Novo Nordisk failed to adequately warn patients and healthcare providers about these serious risks.
While common side effects like nausea are well-documented, the litigation focuses on rarer but potentially life-altering complications. Most cases are still in early stages, with no final verdicts as of early 2026.
Patients who experience severe or persistent symptoms should seek medical attention immediately and discuss their concerns with their doctor. Anyone worried about possible long-term harm may wish to consult a qualified attorney familiar with pharmaceutical litigation.
FAQ
What is the most common side effect named in Ozempic lawsuits?
Severe gastroparesis (stomach paralysis) and ileus (bowel obstruction without physical blockage) appear in the largest number of claims. Plaintiffs describe chronic vomiting, pain, malnutrition, and repeated hospitalizations.
Has anyone won an Ozempic lawsuit yet?
As of January 2026, no major bellwether trials have concluded, and no large public settlements have been announced. Most cases remain in the discovery phase within the multidistrict litigation.
Is temporary nausea part of the Ozempic lawsuits?
No. Ordinary nausea and vomiting are well-known, expected side effects that are clearly listed on the label. Lawsuits focus on much more severe and prolonged gastrointestinal damage.
Can I join an Ozempic lawsuit if I had gallbladder surgery?
Possibly. If you developed gallstones or acute cholecystitis requiring surgery while taking Ozempic, you may qualify to join the litigation. An attorney can review your medical records to determine eligibility.
Does the Ozempic label now warn about gastroparesis and vision loss?
Yes. After 2023–2025 updates, the current label includes warnings about gastroparesis, ileus, gallbladder disorders, and a possible association with NAION (vision loss). The company continues to update safety information as new data emerge.
Hello Friends!
My name is Ahmad, reading books and gaining knowledge about Health, skin and their conditions is my passion and I am here to share my knowledge and experience with you. I hope it’s very helpful for you.
Thank you very much.